secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001104659-25-105633
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics resubmits BLA for ONS-5010 (wet AMD) to FDA after Sept 2025 Type A meeting
--------------------------------------------------------------------------------

- Resubmitted BLA on Nov 3, 2025 for ONS-5010 (LYTENAVA) to treat wet AMD.
- Resubmission follows FDA Type A meeting in Sept 2025; aims to resolve CRL issued Aug 2025.
- CEO Bob Jahr says resubmission marks 'important step forward' for potential near-term U.S. approval.
- Company accelerating commercial efforts in Europe while positioning for U.S. approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925105633/0001104659-25-105633-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465925105633/tm2530088d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105633

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer